Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells

BACKGROUND: Children with Down syndrome (DS) have increased risk for developing AML (DS-AMKL), and they usually experience severe therapy-related toxicities compared to non DS-AMKL. Refractory/relapsed disease has very poor outcome, and patients would benefit from novel, less toxic, therapeutic stra...

Descripción completa

Detalles Bibliográficos
Autores principales: Bista, Ranjan, Lee, David W., Pepper, Oliver B., Azorsa, David O., Arceci, Robert J., Aleem, Eiman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286849/
https://www.ncbi.nlm.nih.gov/pubmed/28143565
http://dx.doi.org/10.1186/s13046-017-0493-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286849/
https://www.ncbi.nlm.nih.gov/pubmed/28143565
http://dx.doi.org/10.1186/s13046-017-0493-5

Ejemplares similares